Decoglurant

{{short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine

| image = Decoglurant structure.svg

| CAS_number = 911115-16-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 5VX4P0JKC5

| ATC_prefix = none

| ATC_suffix =

| PubChem = 71533696

| DrugBank =

| ChemSpiderID = 32695160

| KEGG = D10875

| synonyms = RG1578 and RO4995819

| C=21 | H=11 | F=6 | N=5

| smiles = C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F

| StdInChI = 1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)

| StdInChIKey = DMJHZVARRXJSEG-UHFFFAOYSA-N

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Development terminated

| routes_of_administration =

}}

Decoglurant (INN; development codes RG1578 and RO4995819) is a negative allosteric modulator of the mGlu₂ and mGlu₃ receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.{{cite web | url = http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm | title = Roche – Pipeline | year = 2014 | access-date = 2014-08-01 | archive-date = 2022-10-23 | archive-url = https://web.archive.org/web/20221023214708/https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm | url-status = dead }}{{cite web | url = http://www.roche.com/irp1q14e-annex.pdf | title = Roche Group Development Pipeline | year = 2014 | access-date = 2014-08-01 | url-status = dead | archive-url = https://web.archive.org/web/20140808043650/http://www.roche.com/irp1q14e-annex.pdf | archive-date = 2014-08-08 }} Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results.{{cite web | url = http://www.roche.com/irp150128-annex.pdf | title = Roche – Pipeline | year = 2015 | access-date = 2015-05-14 | archive-url = https://web.archive.org/web/20150501063120/http://www.roche.com/irp150128-annex.pdf | archive-date = 2015-05-01 | url-status = dead }}{{cite journal | url = http://www.pharmaceutical-journal.com/news-and-analysis/features/the-secret-life-of-ketamine/20068151.article | title = The Secret Life of ketamine | vauthors = Lawrence J | date = March 2015 | journal = The Pharmaceutical Journal | volume = 294 | issue = 7854/5}}